髓系细胞触发受体2基因表达与晚期食管鳞癌新辅助放化疗预后的关系  

Relationship between expression of triggering receptors expressed on myeloid cells-2(TREM2)and prognosis of advanced esophageal squamous cell carcinoma(ESCC)with neoadjuvant chemoradiotherapy

作　　者：樊晶 马荣 姚奕妃 FAN Jing;MA Rong;YAO Yifei(Yuncheng Central Hospital,Yuncheng Shanxi 044000,China)

机构地区：[1]运城市中心医院,山西运城044000

出　　处：《新疆医科大学学报》2024年第12期1621-1626,共6页Journal of Xinjiang Medical University

基　　金：山西省大健康产业高质量发展科研专项项目(DJKZKT2023094)。

摘　　要：目的分析髓系细胞触发受体2(TREM2)基因表达与晚期食管鳞癌(ESCC)新辅助放化疗预后的关系。方法收集本院2022年3月至2023年6月收治的175例局部晚期ESCC患者的病例资料进行回顾性分析。所有患者均接受新辅助放化疗+根治性切除术治疗,根据晚期ESCC患者预后分为病理完全缓解(pCR)组与非pCR组。对比两组临床资料与癌组织中TREM2表达水平,分析晚期ESCC新辅助放化疗患者非pCR的影响因素,受试者工作特征曲线(ROC)分析癌组织中TREM2表达水平对晚期ESCC新辅助放化疗患者非pCR的预测价值。结果ESCC癌组织中TREM2表达水平高于癌旁组织(P<0.05)。175例ESCC患者中,pCR率为34.86%(61/175)。pCR组患者年龄≥60岁、N1分期例数占比低于非pCR组(P<0.05)。pCR组癌组织中TREM2表达水平低于非pCR组(P<0.05)。年龄≥60岁(OR=3.184,95%CI:1.670~6.070)、N1分期(OR=3.442,95%CI:1.805~6.563)、癌组织中TREM2表达水平(OR=3.943,95%CI:2.068~7.519)为晚期ESCC新辅助放化疗患者非pCR的独立危险因素(P<0.05)。癌组织中TREM2表达水平预测晚期ESCC新辅助放化疗患者非pCR的ROC曲线下面积为0.844(P<0.05)。结论晚期ESCC患者癌组织中TREM2基因表达上调,癌组织中TREM2表达水平对预测晚期ESCC新辅助放化疗患者预后具有重要价值。ObjectiveTo investigate the relationship between the expression of triggering receptors expressed on myeloid cells-2(TREM2)gene and the prognosis of neoadjuvant chemoradiotherapy in advanced esophageal squamous cell carcinoma(ESCC).MethodsThe data of 175 patients with locally advanced ESCC admitted to the hospital from March 2022 to June 2023 were retrospectively analyzed.All patients received neoadjuvant chemoradiation plus radical resection.According to the prognosis of advanced ESCC patients,the patients were divided into pathological complete response(pCR)group and non-PCR group.The expression level of TREM2 in cancer tissue was compared with the clinical data of the 2 groups.The non-PCR influencing factors of advanced ESCC neoadjuvant chemoradiotherapy were analyzed.The non-PCR predictive value of TREM2 expression in cancer tissues in patients with advanced ESCC neoadjuvant chemoradiotherapy was analyzed using receiver operating characteristic curve(ROC).ResultsThe ESCC cancer tissues with TREM2 expression level was higher than adjacent tissues(P<0.05).In 175 ESCC patients,the pCR rate was 34.86%(61/175).The proportion of N1 stages in pCR group was lower than that in non-PCR group(P<0.05).The pCR group with TREM2 expression level in cancer tissuewas lower than non-PCR group(P<0.05).Age≥60 years(OR=3.184,95%CI:1.670~6.070),N1 stage(OR=3.442,95%CI:1.805~6.563),TREM2 expression level in cancer tissues(OR=3.943,95%CI:2.068~7.519)were non-PCR independent risk factors in patients with advanced ESCC neoadjuvant chemoradiotherapy(P<0.05).The expression level of TREM2 in cancer tissue predicted the ROC area under the curve of non-pCR in patients with advanced ESCC neoadjuvant chemoradiotherapy was 0.844(P<0.05).ConclusionThe expression of TREM2 gene is up-regulated in cancer tissues of advanced ESCC patients,and the level of TREM2 expression in cancer tissue is important for predicting the prognosis of advanced ESCC patients with neoadjuvant chemoradiotherapy.

关 键 词：髓系细胞触发受体2 晚期食管鳞癌 预后 新辅助放化疗 影响因素 预测价值 

分 类 号：R735.1[医药卫生—肿瘤]